Novel Topical Treatment for Postherpetic Neuralgia

带状疱疹后神经痛的新型局部治疗

• 批准号: 6991051
• 负责人: Charles J Gauntt
• 金额: $ 19.69万
• 依托单位: BIOMEDICAL DEVELOPMENT CORPORATION
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2008-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6991051
• 关键词: analgesia; chemotherapy; chronic pain; clinical research; clinical trials; drug delivery systems; drug design /synthesis /production; drug screening /evaluation; human subject; human therapy evaluation; local anesthetics; patient oriented research; polymers; shingles; slow release drug; topical drug application

DESCRIPTION (provided by applicant): The goal of this project is to develop a novel topical drug delivery vehicle to treat postherpetic neuralgia [PHN). PHN is defined as pain in the affected dermatome that persists or appears after the rash of herpes zoster (HZ) has healed. Although many cases of PHN resolve over time, for many patients the pain is chronic, causing a devastating impact on quality of life. Systemic treatments for PHN are associated with undesirable adverse effects, which can be particularly problematic for elderly patients. Topical treatments such as capsaicin cream, acetylsalicylic acid (aspirin), anesthetic creams, and lidocaine patches either require multiple daily applications or are limited in their use due to the potential for elevated systemic absorption of the topical compound. In previous work, Biomedical Development Corporation (BDC) has developed a novel polymer-based coating composition that is useful for several biomedical applications. The coating is capable of sustained topical drug delivery. The objective of this project is to use these coatings as a treatment for the pain associated with postherpetic neuralgia. The Specific Aims of the grant are as follows: Specific Aim 1: Formulate Coatings for the Treatment of Postherpetic Neuralgia Specific Aim 2: Demonstrate Efficacy of Coatings in a Human Clinical Trial Relevance to Public Health: Herpes zoster (shingles) is one of the most common neurologic diseases in the U.S. Although there have been no systematic attempts to investigate the prevalence of post herpetic neuralgia, estimates have ranged from 500,000 to 1 million in the U.S. The incidence of PHN among those with herpes zoster ranges from 10 to 70 percent and increases with advancing age and the intractability of the pain may also increase with age. The incidence of herpes zoster, and therefore the incidence of PHN, is predicted to increase in the coming decades because of both the aging population and as a consequence of childhood varicella vaccination. The ongoing spontaneous pain and particularly the allodynic component of PHN can be debilitating and can lead to co-morbid conditions such as depression, social isolation, anxiety and sleep disturbance, as well as increased health care utilization.

描述（由申请人提供）：该项目的目的是开发一种新型的局部药物输送工具来治疗胸骨后神经痛[PHN）。 PHN被定义为受影响的皮肤病组中的疼痛，在疱疹带状疱疹（Hz）愈合后持续或出现。尽管随着时间的流逝，许多PHN病例都可以解决，但对于许多患者，疼痛是慢性的，对生活质量造成了破坏性的影响。 PHN的全身治疗与不良的不良反应有关，这对于老年患者尤其有问题。局部处理，例如辣椒素霜，乙酰乳清酸（阿司匹林），麻醉剂霜和利多卡因贴剂，要么需要多次每日应用，要么由于局部化合物的全身吸收而可能受到限制。 在先前的工作中，生物医学开发公司（BDC）开发了一种新型的基于聚合物的涂料组成，对几种生物医学应用有用。涂层能够持续局部药物输送。该项目的目的是将这些涂层用作与后螺旋神经痛相关的疼痛的治疗方法。赠款的具体目的如下：特定目的1：为治疗后脑肠胃神经痛特定目的的涂料配制涂料2：在人类临床试验中与公共卫生相关的涂料的功效：疱疹带状疱疹（带状疱疹）是美国最常见的神经学疾病，尽管估计有500000次的神经疾病，但她估计了她的估计性疾病，而这些疾病的预期是估计的，她的疾病是估计的。在美国，有100万个具有疱疹带状疱疹的人的发病率从10％到70％不等，并且随着年龄的增长而增加，疼痛的棘手性也可能随着年龄的增长而增加。由于人口老龄化和由于儿童水痘疫苗的结果，预计疱疹带状疱疹的发生率，因此预计在未来几十年中会增加。持续的自发疼痛，尤其是PHN的异源疼痛可能会使人衰弱，并可能导致抑郁症，社会隔离，焦虑和睡眠障碍等联合发生状况，并增加医疗保健利用。